Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

98 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Pseudomonas aeruginosa serology and risk for re-isolation in the EPIC trial.
Anstead M, Heltshe SL, Khan U, Barbieri JT, Langkamp M, Döring G, Dharia S, Gibson RL, Treggiari MM, Lymp J, Rosenfeld M, Ramsey B. Anstead M, et al. Among authors: heltshe sl. J Cyst Fibros. 2013 Mar;12(2):147-53. doi: 10.1016/j.jcf.2012.08.001. Epub 2012 Sep 1. J Cyst Fibros. 2013. PMID: 22944725 Free PMC article. Clinical Trial.
Evaluating the predictive ability of sweat chloride.
Heltshe SL, Rowe SM, Mayer-Hamblett N. Heltshe SL, et al. J Cyst Fibros. 2014 Jan;13(1):118. doi: 10.1016/j.jcf.2013.07.002. Epub 2013 Aug 3. J Cyst Fibros. 2014. PMID: 23920003 Free article. No abstract available.
A randomized double blind, placebo controlled phase 2 trial of BIIL 284 BS (an LTB4 receptor antagonist) for the treatment of lung disease in children and adults with cystic fibrosis.
Konstan MW, Döring G, Heltshe SL, Lands LC, Hilliard KA, Koker P, Bhattacharya S, Staab A, Hamilton A; Investigators and Coordinators of BI Trial 543.45. Konstan MW, et al. Among authors: heltshe sl. J Cyst Fibros. 2014 Mar;13(2):148-55. doi: 10.1016/j.jcf.2013.12.009. Epub 2014 Jan 17. J Cyst Fibros. 2014. PMID: 24440167 Free PMC article. Clinical Trial.
Clinical mechanism of the cystic fibrosis transmembrane conductance regulator potentiator ivacaftor in G551D-mediated cystic fibrosis.
Rowe SM, Heltshe SL, Gonska T, Donaldson SH, Borowitz D, Gelfond D, Sagel SD, Khan U, Mayer-Hamblett N, Van Dalfsen JM, Joseloff E, Ramsey BW; GOAL Investigators of the Cystic Fibrosis Foundation Therapeutics Development Network. Rowe SM, et al. Among authors: heltshe sl. Am J Respir Crit Care Med. 2014 Jul 15;190(2):175-84. doi: 10.1164/rccm.201404-0703OC. Am J Respir Crit Care Med. 2014. PMID: 24927234 Free PMC article.
Pseudomonas aeruginosa in cystic fibrosis patients with G551D-CFTR treated with ivacaftor.
Heltshe SL, Mayer-Hamblett N, Burns JL, Khan U, Baines A, Ramsey BW, Rowe SM; GOAL (the G551D Observation-AL) Investigators of the Cystic Fibrosis Foundation Therapeutics Development Network. Heltshe SL, et al. Clin Infect Dis. 2015 Mar 1;60(5):703-12. doi: 10.1093/cid/ciu944. Epub 2014 Nov 25. Clin Infect Dis. 2015. PMID: 25425629 Free PMC article.
Outcomes and Treatment of Chronic Methicillin-Resistant Staphylococcus aureus Differs by Staphylococcal Cassette Chromosome mec (SCCmec) Type in Children With Cystic Fibrosis.
Heltshe SL, Saiman L, Popowitch EB, Miller MB, Kloster M, Thompson V, Ferkol TW, Hoover WC, Schechter MS, Muhlebach MS. Heltshe SL, et al. J Pediatric Infect Dis Soc. 2015 Sep;4(3):225-31. doi: 10.1093/jpids/piu048. Epub 2014 Jun 9. J Pediatric Infect Dis Soc. 2015. PMID: 26336603 Free PMC article.
98 results